Short answer: the best-quality evidence does not show that Cerebrolysin improves stroke outcomes. A large randomised trial in Asia reported a neutral primary result, and the most recent Cochrane review concluded that Cerebrolysin and similar peptide mixtures probably make little or no difference to death and may be associated with more non-fatal serious adverse events. There is a substantial preclinical literature on its neurotrophic effects, which is why it remains a laboratory subject. This guide walks through what the trials actually reported, what the laboratory studies add, and why the nature of the product makes it hard to study. It reviews published research. It is not a treatment guide, and Peptides Lab UK supplies Cerebrolysin for laboratory research only.
What Cerebrolysin is, and why that matters
Cerebrolysin is not a single peptide. The Cochrane authors describe it as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain, and it has been widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries. That description carries two implications for researchers.
First, nobody can write down a single sequence and a single mechanism. The preparation is defined by its manufacturing process and by the activities it shows in assays, so results from one preparation cannot be assumed to apply to another. Second, quality control is harder than for a single synthetic peptide, because identity is a profile rather than a mass. If you are reading “Cerebrolysin research” in a catalogue or a blog, it is worth asking what exactly was tested.
This is also why the related peptide P21 exists. Our P21 guide describes how a short tetrapeptide was identified by epitope mapping of Cerebrolysin as an attempt to reproduce a neurotrophic effect in a defined molecule. The contrast shows the problem researchers were trying to solve: a mixture is hard to standardise.
The preclinical work: neurotrophic signals in cells and mice
The reason Cerebrolysin attracted clinical testing is a set of laboratory studies in which it influenced neurotrophic pathways. Three papers give a flavour.
- Rockenstein et al. (Journal of Neuroscience Research, 2006) reported that Cerebrolysin decreased amyloid-beta production in a transgenic mouse model by regulating the maturation of amyloid protein precursor.
- Rockenstein et al. (Acta Neuropathologica, 2007) examined its effects on neurogenesis in an APP transgenic model of Alzheimer’s disease.
- Ubhi et al. (Journal of Neuroscience Research, 2013) reported that Cerebrolysin modulated the pro-nerve growth factor to nerve growth factor ratio and was associated with improvement of cholinergic deficits in a transgenic model.
These studies are useful because they define mechanisms for follow-up, such as neurotrophin signalling and processing of amyloid precursor protein. They are also limited in ways that apply to most preclinical work: specific transgenic models, particular dosing schedules in animals, and endpoints that may not predict clinical outcomes. A positive signal in a mouse model of Alzheimer’s disease says little about acute stroke in a person.
The CASTA trial: a large, neutral result
The most informative single trial is Heiss et al. (Stroke, 2012), the Cerebrolysin Acute Stroke Treatment in Asia (CASTA) study. It was a double-blind, placebo-controlled randomised trial. Patients with acute ischaemic hemispheric stroke were randomised within 12 hours of symptom onset to Cerebrolysin or saline placebo given as an intravenous infusion for 10 days on top of aspirin, and followed for 90 days. The primary end point combined the modified Rankin Scale, the Barthel Index and the NIH Stroke Scale in a global test. In all, 1,070 patients were enrolled, 529 in the Cerebrolysin arm and 541 on placebo.
The confirmatory result was neutral: the abstract states that the primary end point showed no significant difference between groups. The authors reported a post hoc trend favouring Cerebrolysin among patients with more severe strokes (NIHSS above 12), including lower cumulative 90-day mortality in that subgroup, and said this should be confirmed in a further trial. That is a fair thing to say, but it is also a classic example of a post hoc subgroup finding, which carries a higher risk of chance results and cannot be used as proof. A careful reader should hold both statements in mind: the trial was neutral overall, and a hypothesis was generated for further study.
The Cochrane review: the whole body of randomised evidence
For a broader picture, the Cochrane review by Ziganshina and colleagues (2023) is the best single source. It updated earlier versions and included seven randomised trials with 1,773 participants, comparing Cerebrolysin or Cerebrolysin-like agents (one trial tested a related product, Cortexin) started within 48 hours of stroke onset against placebo or no treatment.
Key findings in the abstract:
- Death from any cause: probably little to no difference (risk ratio 0.96, 95% CI 0.65 to 1.41; six trials; moderate-certainty evidence).
- Serious adverse events overall: probably little to no difference (RR 1.16, 95% CI 0.81 to 1.66; three trials; moderate certainty).
- Non-fatal serious adverse events: an increase was reported (RR 2.39, 95% CI 1.10 to 5.23; three trials; moderate certainty).
- Functional outcomes: none of the included studies reported poor functional outcome as defined by the review (death or dependence), quality of life, or time to return to work.
The review’s authors also documented concerns about trial quality: the risk of bias for selective outcome reporting was unclear across the Cerebrolysin studies, blinding was unclear in several, and the manufacturer supported three of the multicentre studies. Their conclusion was that Cerebrolysin and similar mixtures probably have no beneficial effect on all-cause death in acute ischaemic stroke, and that there may be an increase in non-fatal serious adverse events.
Cochrane reviews are updated as new evidence appears, so a current reader should check for the latest version rather than rely on this summary.
So what are the reported risks?
The question “what are the risks of Cerebrolysin” is searched widely. A reasonable, research-based answer has three layers.
- What trials reported. In the Cochrane analysis the notable signal was a higher number of people with non-fatal serious adverse events, and it was more pronounced in a high-total-dose schedule subgroup. The abstract does not break these events down further, so the specific kinds of event cannot be summarised from it.
- What trials could not report. Long-term safety, quality-of-life effects and many functional outcomes were not reported in the included trials.
- What the product is. An animal-derived mixture raises standardisation, batch-consistency and immunological questions that do not apply to a synthetic single peptide. Those are reasons for caution in interpreting any single batch’s behaviour.
None of this is a recommendation. This site does not advise on treatment, and Cerebrolysin is not something we offer for use in people.
What this means for laboratory work
For researchers, Cerebrolysin is a tool in neuroscience models: neuronal culture, neurotrophin signalling, amyloid processing, and comparisons with defined peptides. Practical points follow from the above.
- Report the preparation. Name the manufacturer, lot and form, because “Cerebrolysin” is not a defined compound.
- Plan concentrations in mass or protein terms and say so. A mixture has no single molecular weight, so molarity is not meaningful. The peptide calculator handles mass-based dilutions for laboratory use.
- Use matched controls. Include vehicle controls and, where possible, defined comparators such as the neurotrophic peptides covered in our Cerebrolysin research overview or in our Semax guide.
- Check the certificate. Batches from Peptides Lab UK of Cerebrolysin for laboratory research are HPLC & COA Verified. For a mixture, a certificate documents the profile for that batch, not a single-molecule identity.
Frequently asked questions
If you are weighing UK peptides suppliers, our guide to buying peptides in the UK and the best research peptides UK scorecard explain what documentation to look for.
How does Cerebrolysin help with stroke recovery?
The best-quality evidence does not show that it does. The CASTA trial of 1,070 patients reported a neutral primary result, and the 2023 Cochrane review concluded that Cerebrolysin and similar mixtures probably have no beneficial effect on all-cause death in acute ischaemic stroke. Preclinical studies describe neurotrophic effects in cells and mice, which is why it remains a research subject.
What are the risks of Cerebrolysin?
The Cochrane review reported moderate-certainty evidence of an increase in non-fatal serious adverse events (risk ratio 2.39), with little or no difference in total serious adverse events or death. Long-term safety was not reported. It is an animal-derived mixture, which also raises standardisation questions.
What is Cerebrolysin used to treat?
In some countries, mainly in Eastern Europe and Asia, it has been used in acute ischaemic stroke and other neurological conditions. This is a description of published practice and not a recommendation; the evidence reviewed above does not show clear benefit in stroke, and Peptides Lab UK supplies it for laboratory research only.
Is Cerebrolysin a single peptide?
No. It is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain, so it has no single sequence or molecular weight.
Why does the CASTA subgroup result not prove benefit?
The subgroup finding in patients with more severe strokes came from a post hoc analysis after the primary end point was neutral. Post hoc subgroups have a higher risk of chance findings, and the authors themselves said a further trial was needed.
Peptides Lab UK products are supplied for laboratory research use only, not for human or veterinary use. This article summarises published research and is not medical advice.